bluuebunny/crossref_metadata_2025 huggingface dataset:
Mathematical Analysis of Malaria Epidemic: Asymptotic Stability With Cost‐Effectiveness Study
Authors: Nana-Kyere Sacrifice , Seidu Baba , Nantomah Kwara
Published: July 2024

Malaria is an old, curable vector‐borne disease that is devastating in the tropics and subtropical regions of the world. The disease has unmatched complications in the human host, especially in children. Mathematical models of infectious diseases have been the steering wheel, driving scientists towards elucidation of the dynamic behaviour of epidemics and providing tailored strategic management of diseases. With the ongoing vaccination programs for vector‐borne diseases, the research proposes a nonlinear differential equation model for the malaria disease that provides public health with a shift from the classical understanding of nonpharmaceutical preventive malaria control to pharmaceutical measures of vaccines. The asymptotic dynamic behaviour of the model is studied at the model’s equilibria. The bifurcation type invoked at the disease‐free state is analysed, and the result revealed that the convention that is the condition for eradicating the disease is not always sufficient when the system undergoes backward bifurcation. Furthermore, sensitivity analysis was investigated to quantify the amount of influence each parameter has on . With the Latin hypercube sampling and partial rank correlation coefficient method, the uncertainty in is computed with a 95% confidence interval, with the mean, and 5th and 95th percentiles, respectively, simulated as 0.143788, 0.01545, and 0.41491. An intervention model was derived from the nonintervention model to experiment with and evaluate the respective effects of the various pairings of interventions on the dynamics of the disease. Lastly, an in‐depth cost analysis was studied to identify the most cost‐effective intervention regarding rewarding the desired outcome. From the analysis, we recommend that besides the nonpharmaceutical measure of bed nets and insecticide spray, public health should target the pharmaceutical intervention of vaccine as it can close the gap in malaria prevention.
Association between Dietary Potassium Intake and Nonalcoholic Fatty Liver Disease and Advanced Hepatic Fibrosis in U.S. Adults
Authors: Chen Hao-Kai , Lan Qi-Wen , Li Yu-Jia , Xin Qing , Luo Run-Qi , Wang Jun-Jie
Published: July 2024

Introduction. The correlation between potassium and nonalcoholic fatty liver disease (NAFLD) is currently still poorly understood. We conducted this study to explore the correlation between dietary potassium intake and NAFLD, as well as advanced hepatic fibrosis (AHF). The study also sought to identify any potential interactions. Methods. The data employed in this study were obtained from the National Health and Nutrition Examination Survey (NHANES) program, encompassing a period from 2007 to 2018. Employing the multiple logistic regression analysis, we evaluated the association of dietary potassium intake with NAFLD and AHF. Subsequently, stratification analysis, based on demographic variables, was constructed so as to assess the stability of the results. In addition, potential interaction effects were assessed by interaction tests. Results. A total of 9443 participants were included in the analysis. The mean age of the participants was 50.4 years, and their daily mean dietary potassium and vitamin C intake was 2556.49 mg and 82.93 mg, respectively. Following comprehensive statistical analyses, the findings indicated a negative correlation between dietary potassium intake and both NAFLD and AHF. Participants in Q4 group with dietary potassium intake exhibited a 31% and 42% reduction in the odds of developing NAFLD and AHF, respectively, in comparison to Q1 group. An interaction effect of dietary vitamin C intake was observed in the association between dietary potassium intake and NAFLD. The results imply that high dietary vitamin C intake augment the inverse relationship between dietary potassium intake and NAFLD. Conclusion. Dietary potassium intake was found to have an inverse association with the odds of both NAFLD and AHF. The association between dietary potassium intake and NAFLD was amplified by the presence of vitamin C in the diet.
CFD Simulation and ANN Prediction of Hydrogen Leakage and Diffusion Behavior in a Hydrogen Refuelling Station
Authors: Xiao Jinsheng , Xu Nianfeng , Li Yaze , Li Guodong , Liu Min , Tong Liang , Yuan Chengqing , Li Xuefang , Yang Tianqi
Published: July 2024

Hydrogen refueling station (HRS) is an essential part of the infrastructure for promoting the hydrogen economy. Since hydrogen is a flammable and explosive gas, hydrogen released from high‐pressure hydrogen storage equipment in HRS will likely cause combustion or explosion accidents. Studying high‐pressure hydrogen leakage in HRS is a prerequisite for promoting hydrogen fuel cell vehicles and HRS. A computational fluid dynamics (CFD) model of an HRS in a demonstrated project in Ningbo, China, was established on the ANSYS FLUENT software platform. The CFD model for hydrogen leakage simulation was validated by comparing the simulation results with experimental data in the literature. The effects of the direction and mass flow rate of the hydrogen leakage jet, as well as the direction and speed of ambient wind, on hydrogen diffusion behavior were investigated. The spreading distances of the flammable hydrogen cloud were predicted using an artificial neural network for horizontal leakage. The results show that the jet direction strongly affected the flammable cloud flow. The greater the mass flow rate of the leak, the greater the hydrogen dispersion distance and the volume of the flammable hydrogen cloud. At a hydrogen leakage mass flow rate of 4.5589 kg/s, the volume of the hydrogen flammable cloud reached 6,140.46 m3 at 30 s of leakage. The ambient wind speed has complicated effects on spreading the flammable cloud. The wind makes the flammable cloud move in certain directions, and the higher wind speed accelerates the diffusion of the flammable gas in the air. The results of the study can be used as a reference for the study of high‐pressure hydrogen leakage in HRS and will play an important role in the safe demonstration of the studied project.
Supplementary Table 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Authors: Boumelha Jesse , de Castro Andrea , Bah Nourdine , Cha Hongui , de Carné Trécesson Sophie , Rana Sareena , Tomaschko Mona , Anastasiou Panayiotis , Mugarza Edurne , Moore Christopher , Goldstone Robert , East Phil , Litchfield Kevin , Lee Se-Hoon , Molina-Arcas Miriam , Downward Julian
Published: July 2024

Supplementary Table S3. sgRNA sequences for CRISPR-Cas9 gene knockout
Supplementary Figure 8 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Authors: Boumelha Jesse , de Castro Andrea , Bah Nourdine , Cha Hongui , de Carné Trécesson Sophie , Rana Sareena , Tomaschko Mona , Anastasiou Panayiotis , Mugarza Edurne , Moore Christopher , Goldstone Robert , East Phil , Litchfield Kevin , Lee Se-Hoon , Molina-Arcas Miriam , Downward Julian
Published: July 2024

Supplementary Figure 8. COX-2/PGE2 pathway inhibition remodels the TME and enhances the efficacy of ICB
Supplementary Table 3 from Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal Metaplasia
Authors: Neuß Thorsten , Chen Min-Chun , Wirges Nils , Usluer Sinem , Oellinger Rupert , Lier Svenja , Dudek Michael , Madl Tobias , Jastroch Martin , Steiger Katja , Schmitz Werner , Einwächter Henrik , Schmid Roland M.
Published: July 2024

Table of Msigdb Hallmark gene sets and their correlation with observed transdifferentiation rate
Supplementary Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Authors: Boumelha Jesse , de Castro Andrea , Bah Nourdine , Cha Hongui , de Carné Trécesson Sophie , Rana Sareena , Tomaschko Mona , Anastasiou Panayiotis , Mugarza Edurne , Moore Christopher , Goldstone Robert , East Phil , Litchfield Kevin , Lee Se-Hoon , Molina-Arcas Miriam , Downward Julian
Published: July 2024

Supplementary Figure 4. COX-2 deficient tumors are sensitized to anti-tumor immunity
Supplementary Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Authors: Boumelha Jesse , de Castro Andrea , Bah Nourdine , Cha Hongui , de Carné Trécesson Sophie , Rana Sareena , Tomaschko Mona , Anastasiou Panayiotis , Mugarza Edurne , Moore Christopher , Goldstone Robert , East Phil , Litchfield Kevin , Lee Se-Hoon , Molina-Arcas Miriam , Downward Julian
Published: July 2024

Supplementary Figure 2. KRAS-driven inhibition of tumor-intrinsic IFN signaling promotes immune evasion
Fig. S7 from Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal Metaplasia
Authors: Neuß Thorsten , Chen Min-Chun , Wirges Nils , Usluer Sinem , Oellinger Rupert , Lier Svenja , Dudek Michael , Madl Tobias , Jastroch Martin , Steiger Katja , Schmitz Werner , Einwächter Henrik , Schmid Roland M.
Published: July 2024

Mitochondrial regulator PDH is activated and required for ADM and serine levels correlate with mitochondrial activity
Figure 5 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Authors: Boumelha Jesse , de Castro Andrea , Bah Nourdine , Cha Hongui , de Carné Trécesson Sophie , Rana Sareena , Tomaschko Mona , Anastasiou Panayiotis , Mugarza Edurne , Moore Christopher , Goldstone Robert , East Phil , Litchfield Kevin , Lee Se-Hoon , Molina-Arcas Miriam , Downward Julian
Published: July 2024

Dual inhibition of EP2 and EP4 synergizes with ICB. A–C, M1/M2 macrophage ratio (A), percentage of Arg1+ CD11b+ TAMs (B), and percentage of CD69+ CD8+ T cells (C) in KPAR tumors treated twice daily for 7 days with 100 mg/kg TPST-1495. D, Kaplan–Meier survival of mice treated intraperitoneally with 200 μg anti-PD1 and/or twice daily oral gavage of 100 mg/kg TPST-1495 after orthotopic transplantation of KPAR cells, n = 8–12 mice per group. TPST-1495 treatment was initiated on day 7 and anti-PD1 began on day 10 and was administered twice weekly for a maximum of 3 weeks. Analysis of survival curves was carried out using the log-rank (Mantel–Cox) test. E, Heatmap showing hierarchical clustering of KPAR tumors treated for 7 days with TPST-1495 and/or anti-PD1 based on mRNA expression of antitumor immunity genes assessed by qPCR. F, mRNA expression by qPCR of immune-related genes in KPAR tumors treated as shown in E. Data are represented as mean ± SEM for A–C and F, n = 7–8 mice per group. Statistics were calculated using unpaired, two-tailed Student t test (A–C) or one-way ANOVA, FDR 0.05 (F). ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Fig. S3 from Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal Metaplasia
Authors: Neuß Thorsten , Chen Min-Chun , Wirges Nils , Usluer Sinem , Oellinger Rupert , Lier Svenja , Dudek Michael , Madl Tobias , Jastroch Martin , Steiger Katja , Schmitz Werner , Einwächter Henrik , Schmid Roland M.
Published: July 2024

Downregulation of OxPhos during ADM formation
Table S6 from HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer
Authors: Gnanapragasam Ansley , Kirbizakis Eftyhios , Li Anna , White Kyle H. , Mortenson Katelyn L. , Cavalcante de Moura Juliana , Jawhar Wajih , Yan Yifei , Falter Reilly , Russett Colleen , Giannias Betty , Camilleri-Broët Sophie , Bertos Nicholas , Cools-Lartigue Jonathan , Garzia Livia , Sangwan Veena , Ferri Lorenzo , Zhang Xiaoyang , Bailey Swneke D.
Published: July 2024

SNV filtering using HiChIP data referenced in manuscript
Table S5 from HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer
Authors: Gnanapragasam Ansley , Kirbizakis Eftyhios , Li Anna , White Kyle H. , Mortenson Katelyn L. , Cavalcante de Moura Juliana , Jawhar Wajih , Yan Yifei , Falter Reilly , Russett Colleen , Giannias Betty , Camilleri-Broët Sophie , Bertos Nicholas , Cools-Lartigue Jonathan , Garzia Livia , Sangwan Veena , Ferri Lorenzo , Zhang Xiaoyang , Bailey Swneke D.
Published: July 2024

List of genes and their LRT scores surrounding each GWAS index SNV.
Figure S5 from IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer
Authors: Xia Jie , Zhang Lixing , Peng Xilei , Tu Juchuanli , Li Siqin , He Xueyan , Li Fengkai , Qiang Jiankun , Dong Haonan , Deng Qiaodan , Liu Cuicui , Xu Jiahui , Zhang Rui , Liu Quentin , Hu Guohong , Liu Chong , Jiang Yi-Zhou , Shao Zhi-Ming , Chen Ceshi , Liu Suling
Published: July 2024

Supplementary Figure S5
Table S4 from HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer
Authors: Gnanapragasam Ansley , Kirbizakis Eftyhios , Li Anna , White Kyle H. , Mortenson Katelyn L. , Cavalcante de Moura Juliana , Jawhar Wajih , Yan Yifei , Falter Reilly , Russett Colleen , Giannias Betty , Camilleri-Broët Sophie , Bertos Nicholas , Cools-Lartigue Jonathan , Garzia Livia , Sangwan Veena , Ferri Lorenzo , Zhang Xiaoyang , Bailey Swneke D.
Published: July 2024

Primer List
Figure S4 from IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer
Authors: Xia Jie , Zhang Lixing , Peng Xilei , Tu Juchuanli , Li Siqin , He Xueyan , Li Fengkai , Qiang Jiankun , Dong Haonan , Deng Qiaodan , Liu Cuicui , Xu Jiahui , Zhang Rui , Liu Quentin , Hu Guohong , Liu Chong , Jiang Yi-Zhou , Shao Zhi-Ming , Chen Ceshi , Liu Suling
Published: July 2024

Supplementary Figure S4
Table S3 from HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer
Authors: Gnanapragasam Ansley , Kirbizakis Eftyhios , Li Anna , White Kyle H. , Mortenson Katelyn L. , Cavalcante de Moura Juliana , Jawhar Wajih , Yan Yifei , Falter Reilly , Russett Colleen , Giannias Betty , Camilleri-Broët Sophie , Bertos Nicholas , Cools-Lartigue Jonathan , Garzia Livia , Sangwan Veena , Ferri Lorenzo , Zhang Xiaoyang , Bailey Swneke D.
Published: July 2024

List of files used from ENCODE
Figure S1 from HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer
Authors: Gnanapragasam Ansley , Kirbizakis Eftyhios , Li Anna , White Kyle H. , Mortenson Katelyn L. , Cavalcante de Moura Juliana , Jawhar Wajih , Yan Yifei , Falter Reilly , Russett Colleen , Giannias Betty , Camilleri-Broët Sophie , Bertos Nicholas , Cools-Lartigue Jonathan , Garzia Livia , Sangwan Veena , Ferri Lorenzo , Zhang Xiaoyang , Bailey Swneke D.
Published: July 2024

Expression of UXS1 in normal and tumor tissues.
Figure S6 from ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
Authors: Sicinska Ewa , Kola Vijaya S.R. , Kerfoot Joseph A. , Taddei Madeleine L. , Al-Ibraheemi Alyaa , Hsieh Yi-Hsuan , Church Alanna J. , Landesman-Bollag Esther , Landesman Yosef , Hemming Matthew L.
Published: July 2024

Figure S6. H3K27ac ChIP-seq, input and gene expression of ASPSCR1 and TFE3.
Figure S4 from ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
Authors: Sicinska Ewa , Kola Vijaya S.R. , Kerfoot Joseph A. , Taddei Madeleine L. , Al-Ibraheemi Alyaa , Hsieh Yi-Hsuan , Church Alanna J. , Landesman-Bollag Esther , Landesman Yosef , Hemming Matthew L.
Published: July 2024

Figure S4. Comparative ASPS pathway and gene expression enrichment.
Figure S3 from ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
Authors: Sicinska Ewa , Kola Vijaya S.R. , Kerfoot Joseph A. , Taddei Madeleine L. , Al-Ibraheemi Alyaa , Hsieh Yi-Hsuan , Church Alanna J. , Landesman-Bollag Esther , Landesman Yosef , Hemming Matthew L.
Published: July 2024

Figure S3. ASPS ranked enhancer plots.
Figure S2 from ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
Authors: Sicinska Ewa , Kola Vijaya S.R. , Kerfoot Joseph A. , Taddei Madeleine L. , Al-Ibraheemi Alyaa , Hsieh Yi-Hsuan , Church Alanna J. , Landesman-Bollag Esther , Landesman Yosef , Hemming Matthew L.
Published: July 2024

Figure S2. Enhancer landscape in ASPS
Figure S14 from ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
Authors: Sicinska Ewa , Kola Vijaya S.R. , Kerfoot Joseph A. , Taddei Madeleine L. , Al-Ibraheemi Alyaa , Hsieh Yi-Hsuan , Church Alanna J. , Landesman-Bollag Esther , Landesman Yosef , Hemming Matthew L.
Published: July 2024

Figure S14. ATAC-seq profiles and gene expression at regions with altered DNA accessibility following dTAG13 treatment.
Figure S1 from ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
Authors: Sicinska Ewa , Kola Vijaya S.R. , Kerfoot Joseph A. , Taddei Madeleine L. , Al-Ibraheemi Alyaa , Hsieh Yi-Hsuan , Church Alanna J. , Landesman-Bollag Esther , Landesman Yosef , Hemming Matthew L.
Published: July 2024

Figure S1. PPARGC1A and select immune gene expression in ASPS
Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis
Authors: Shrestha Raj K. , Nassar Zeyad D. , Hanson Adrienne R. , Iggo Richard , Townley Scott L. , Dehairs Jonas , Mah Chui Y. , Helm Madison , Alizadeh-Ghodsi Mohammadreza , Pickering Marie , Ghesquière Bart , Watt Matthew J. , Quek Lake-Ee , Hoy Andrew J. , Tilley Wayne D. , Swinnen Johannes V. , Butler Lisa M. , Selth Luke A.
Published: July 2024

List of genes encoding enzymes with a putative role in lipid metabolism
Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis
Authors: Shrestha Raj K. , Nassar Zeyad D. , Hanson Adrienne R. , Iggo Richard , Townley Scott L. , Dehairs Jonas , Mah Chui Y. , Helm Madison , Alizadeh-Ghodsi Mohammadreza , Pickering Marie , Ghesquière Bart , Watt Matthew J. , Quek Lake-Ee , Hoy Andrew J. , Tilley Wayne D. , Swinnen Johannes V. , Butler Lisa M. , Selth Luke A.
Published: July 2024

Table S1 - list of primers used in the study
Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis
Authors: Shrestha Raj K. , Nassar Zeyad D. , Hanson Adrienne R. , Iggo Richard , Townley Scott L. , Dehairs Jonas , Mah Chui Y. , Helm Madison , Alizadeh-Ghodsi Mohammadreza , Pickering Marie , Ghesquière Bart , Watt Matthew J. , Quek Lake-Ee , Hoy Andrew J. , Tilley Wayne D. , Swinnen Johannes V. , Butler Lisa M. , Selth Luke A.
Published: July 2024

ACSM1 and ACSM3 knockdown causes LNCaP cell death.
Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis
Authors: Shrestha Raj K. , Nassar Zeyad D. , Hanson Adrienne R. , Iggo Richard , Townley Scott L. , Dehairs Jonas , Mah Chui Y. , Helm Madison , Alizadeh-Ghodsi Mohammadreza , Pickering Marie , Ghesquière Bart , Watt Matthew J. , Quek Lake-Ee , Hoy Andrew J. , Tilley Wayne D. , Swinnen Johannes V. , Butler Lisa M. , Selth Luke A.
Published: July 2024

Efficacy of siRNAs targeting ACSM1 and ACSM3.
Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis
Authors: Shrestha Raj K. , Nassar Zeyad D. , Hanson Adrienne R. , Iggo Richard , Townley Scott L. , Dehairs Jonas , Mah Chui Y. , Helm Madison , Alizadeh-Ghodsi Mohammadreza , Pickering Marie , Ghesquière Bart , Watt Matthew J. , Quek Lake-Ee , Hoy Andrew J. , Tilley Wayne D. , Swinnen Johannes V. , Butler Lisa M. , Selth Luke A.
Published: July 2024

Quantification of medium chain fatty acids by mass spectrometry
Supplementary Table 2 from A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis
Authors: Oatman Nicole , Gawali Mruniya V. , Congrove Sunny , Cáceres Román , Sukumaran Abitha , Gupta Nishtha , Murugesan Narmadha , Arora Priyanka , Subramanian Srividhya , Choi Kwangmin , Abdel-Malek Zalfa , Reisz Julie A. , Stephenson Daniel , Amaravadi Ravi , Desai Pankaj , D’Alessandro Angelo , Komurov Kakajan , Dasgupta Biplab
Published: July 2024

Supplementary Table 2
Supplementary Table 1 from A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis
Authors: Oatman Nicole , Gawali Mruniya V. , Congrove Sunny , Cáceres Román , Sukumaran Abitha , Gupta Nishtha , Murugesan Narmadha , Arora Priyanka , Subramanian Srividhya , Choi Kwangmin , Abdel-Malek Zalfa , Reisz Julie A. , Stephenson Daniel , Amaravadi Ravi , Desai Pankaj , D’Alessandro Angelo , Komurov Kakajan , Dasgupta Biplab
Published: July 2024

Supplementary Table 1
Supplementary Fig 6 from A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis
Authors: Oatman Nicole , Gawali Mruniya V. , Congrove Sunny , Cáceres Román , Sukumaran Abitha , Gupta Nishtha , Murugesan Narmadha , Arora Priyanka , Subramanian Srividhya , Choi Kwangmin , Abdel-Malek Zalfa , Reisz Julie A. , Stephenson Daniel , Amaravadi Ravi , Desai Pankaj , D’Alessandro Angelo , Komurov Kakajan , Dasgupta Biplab
Published: July 2024

Supplementary Fig 6
Supplementary Fig 2 from A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis
Authors: Oatman Nicole , Gawali Mruniya V. , Congrove Sunny , Cáceres Román , Sukumaran Abitha , Gupta Nishtha , Murugesan Narmadha , Arora Priyanka , Subramanian Srividhya , Choi Kwangmin , Abdel-Malek Zalfa , Reisz Julie A. , Stephenson Daniel , Amaravadi Ravi , Desai Pankaj , D’Alessandro Angelo , Komurov Kakajan , Dasgupta Biplab
Published: July 2024

Supplementary Fig 2
Supplementary Fig 1 from A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis
Authors: Oatman Nicole , Gawali Mruniya V. , Congrove Sunny , Cáceres Román , Sukumaran Abitha , Gupta Nishtha , Murugesan Narmadha , Arora Priyanka , Subramanian Srividhya , Choi Kwangmin , Abdel-Malek Zalfa , Reisz Julie A. , Stephenson Daniel , Amaravadi Ravi , Desai Pankaj , D’Alessandro Angelo , Komurov Kakajan , Dasgupta Biplab
Published: July 2024

Supplementary Fig 1
Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis
Authors: Shrestha Raj K. , Nassar Zeyad D. , Hanson Adrienne R. , Iggo Richard , Townley Scott L. , Dehairs Jonas , Mah Chui Y. , Helm Madison , Alizadeh-Ghodsi Mohammadreza , Pickering Marie , Ghesquière Bart , Watt Matthew J. , Quek Lake-Ee , Hoy Andrew J. , Tilley Wayne D. , Swinnen Johannes V. , Butler Lisa M. , Selth Luke A.
Published: July 2024

Effect of medium chain fatty acids on prostate cancer cells.
Data from A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis
Authors: Oatman Nicole , Gawali Mruniya V. , Congrove Sunny , Cáceres Román , Sukumaran Abitha , Gupta Nishtha , Murugesan Narmadha , Arora Priyanka , Subramanian Srividhya , Choi Kwangmin , Abdel-Malek Zalfa , Reisz Julie A. , Stephenson Daniel , Amaravadi Ravi , Desai Pankaj , D’Alessandro Angelo , Komurov Kakajan , Dasgupta Biplab
Published: July 2024

Abstract
The genetic landscape of cancer cells can lead to specific metabolic dependencies for tumor growth. Dietary interventions represent an attractive strategy to restrict the availability of key nutrients to tumors. In this study, we identified that growth of a subset of melanoma was severely restricted by a rationally designed combination therapy of a stearoyl-CoA desaturase (SCD) inhibitor with an isocaloric low-oleic acid diet. Despite its importance in oncogenesis, SCD underwent monoallelic codeletion along with PTEN on chromosome 10q in approximately 47.5% of melanoma, and the other SCD allele was methylated, resulting in very low-SCD expression. Although this SCD-deficient subset was refractory to SCD inhibitors, the subset of PTEN wild-type melanoma that retained SCD was sensitive. As dietary oleic acid could potentially blunt the effect of SCD inhibitors, a low oleic acid custom diet was combined with an SCD inhibitor. The combination reduced monounsaturated fatty acids and increased saturated fatty acids, inducing robust apoptosis and growth suppression and inhibiting lung metastasis with minimal toxicity in preclinical mouse models of PTEN wild-type melanoma. When combined with anti-PD1 immunotherapy, the SCD inhibitor improved T-cell functionality and further constrained melanoma growth in mice. Collectively, these results suggest that optimizing SCD inhibitors with diets low in oleic acid may offer a viable and efficacious therapeutic approach for improving melanoma treatment.

Significance: Blockade of endogenous production of fatty acids essential for melanoma combined with restriction of dietary intake blocks tumor growth and enhances response to immunotherapy, providing a rational drug–diet treatment regimen for melanoma.
Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal Metaplasia
Authors: Neuß Thorsten , Chen Min-Chun , Wirges Nils , Usluer Sinem , Oellinger Rupert , Lier Svenja , Dudek Michael , Madl Tobias , Jastroch Martin , Steiger Katja , Schmitz Werner , Einwächter Henrik , Schmid Roland M.
Published: July 2024

Metabolic reprogramming is a hallmark of cancer and is crucial for cancer progression, making it an attractive therapeutic target. Understanding the role of metabolic reprogramming in cancer initiation could help identify prevention strategies. To address this, we investigated metabolism during acinar-to-ductal metaplasia (ADM), the first step of pancreatic carcinogenesis. Glycolytic markers were elevated in ADM lesions compared with normal tissue from human samples. Comprehensive metabolic assessment in three mouse models with pancreas-specific activation of KRAS, PI3K, or MEK1 using Seahorse measurements, nuclear magnetic resonance metabolome analysis, mass spectrometry, isotope tracing, and RNA sequencing analysis revealed a switch from oxidative phosphorylation to glycolysis in ADM. Blocking the metabolic switch attenuated ADM formation. Furthermore, mitochondrial metabolism was required for de novo synthesis of serine and glutathione (GSH) but not for ATP production. MYC mediated the increase in GSH intermediates in ADM, and inhibition of GSH synthesis suppressed ADM development. This study thus identifies metabolic changes and vulnerabilities in the early stages of pancreatic carcinogenesis.

Significance: Metabolic reprogramming from oxidative phosphorylation to glycolysis mediated by MYC plays a crucial role in the development of pancreatic cancer, revealing a mechanism driving tumorigenesis and potential therapeutic targets.

See related commentary by Storz, p. 2225
Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study
Authors: Norris Ruth P. , Dew Rosie , Greystoke Alastair , Cresti Nicola , Cain Henry , Todd Adam , Sharp Linda
Published: July 2024

Background:

Sociodemographic disparities in traditional breast cancer treatment receipt in nonpublicly funded healthcare systems are well documented. This study investigated trastuzumab receipt by sociodemographic factors within a female, HER2+ breast cancer population in England’s publicly funded National Health Service.

Methods:

The English national population-based cancer registry and linked Systemic Anti-Cancer Therapy database identified 36,985 women with HER2+ invasive breast cancer diagnosed between January 1, 2012 and December 31, 2017. Multivariable logistic regression determined the likelihood of trastuzumab receipt in early and metastatic disease by the deprivation category of area of residence and other sociodemographic characteristics.

Results:

Early-stage trastuzumab receipt followed a socioeconomic gradient. Women residing in the most deprived areas were 10% less likely to receive trastuzumab [multivariable OR 0.90; 95% confidence interval (CI), 0.83–0.98] compared with women residing in the least deprived areas. In both early and metastatic disease, trastuzumab receipt was less likely in older women with more comorbidities, estrogen receptor–positive disease, and who were not discussed at a multidisciplinary team meeting.

Conclusions:

Despite the provision of free care at the point of delivery in England, sociodemographic disparities in early-stage HER2+ trastuzumab receipt occur. Further research determining how inequities contribute to disparities in outcomes is warranted to ensure optimized trastuzumab use for all.

Impact:

Fair access to novel cancer treatments regardless of place of residence, sociodemographic characteristics, and/or cancer stage requires prioritization in future cancer improvement policies.

See related In the Spotlight, p. 1259
Supplementary Table S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
Authors: Parikh Aparna R. , Chee Bryant H. , Tsai Jill , Rich Thereasa A. , Price Kristin S. , Patel Sonia A. , Zhang Li , Ibrahim Faaiz , Esquivel Mikaela , Van Seventer Emily E. , Jarnagin Joy X. , Raymond Victoria M. , Corvera Carlos U. , Hirose Kenzo , Nakakura Eric K. , Corcoran Ryan B. , Van Loon Katherine , Atreya Chloe E.
Published: July 2024

Supplementary Table S2. Demographics, clinicopathologic and procedure-related features table. Table depicts study participants in primary timepoint analysis.
Supplementary Figure S4 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
Authors: Parikh Aparna R. , Chee Bryant H. , Tsai Jill , Rich Thereasa A. , Price Kristin S. , Patel Sonia A. , Zhang Li , Ibrahim Faaiz , Esquivel Mikaela , Van Seventer Emily E. , Jarnagin Joy X. , Raymond Victoria M. , Corvera Carlos U. , Hirose Kenzo , Nakakura Eric K. , Corcoran Ryan B. , Van Loon Katherine , Atreya Chloe E.
Published: July 2024

Supplementary Figure S4. Survival outcomes and recurrence rates stratified by CEA status.
Supplementary Figure S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
Authors: Parikh Aparna R. , Chee Bryant H. , Tsai Jill , Rich Thereasa A. , Price Kristin S. , Patel Sonia A. , Zhang Li , Ibrahim Faaiz , Esquivel Mikaela , Van Seventer Emily E. , Jarnagin Joy X. , Raymond Victoria M. , Corvera Carlos U. , Hirose Kenzo , Nakakura Eric K. , Corcoran Ryan B. , Van Loon Katherine , Atreya Chloe E.
Published: July 2024

Supplementary Figure S2. Kaplan-Meier curves for patients with pre-procedure ctDNA stratified by ctDNA status.
Supplementary Table S8 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Authors: Peng Xiaoqi , Zhao Hongbo , Ye Lijuan , Hou Fei , Yi Zihan , Ren Yanxin , Lu Lin , Chen Fukun , Lv Juan , Wang Yinghui , Cai Haolin , Zheng Xihua , Yang Qing , Chen Ting
Published: July 2024

Table S8. NRI and IDI for three prediction model for the risk of DTC lung metastasis
Supplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Authors: Peng Xiaoqi , Zhao Hongbo , Ye Lijuan , Hou Fei , Yi Zihan , Ren Yanxin , Lu Lin , Chen Fukun , Lv Juan , Wang Yinghui , Cai Haolin , Zheng Xihua , Yang Qing , Chen Ting
Published: July 2024

Table S6. Proteins with degree>40 in the PPI network
Supplementary Table S6 from Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial
Authors: Tang Tingxi , Zhou Zhenhua , Chen Min , Li Nan , Sun Jianda , Chen Zekai , Xiao Ting , Wang Xiaoqing , Zhang Longshan , Wang Yingqiao , Zhang Hanbin , Zheng Xiuting , Chen Bei , Ye Feng , Guan Jian
Published: July 2024

Supplementary Table S6 Performance metrics for prediction models in the discovery cohort
Supplementary Table S3 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Authors: Peng Xiaoqi , Zhao Hongbo , Ye Lijuan , Hou Fei , Yi Zihan , Ren Yanxin , Lu Lin , Chen Fukun , Lv Juan , Wang Yinghui , Cai Haolin , Zheng Xihua , Yang Qing , Chen Ting
Published: July 2024

Table S3. Conditions for setting up PRM quantitative peptide segments
Supplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Authors: Peng Xiaoqi , Zhao Hongbo , Ye Lijuan , Hou Fei , Yi Zihan , Ren Yanxin , Lu Lin , Chen Fukun , Lv Juan , Wang Yinghui , Cai Haolin , Zheng Xihua , Yang Qing , Chen Ting
Published: July 2024

Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
Supplementary Table S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Authors: Peng Xiaoqi , Zhao Hongbo , Ye Lijuan , Hou Fei , Yi Zihan , Ren Yanxin , Lu Lin , Chen Fukun , Lv Juan , Wang Yinghui , Cai Haolin , Zheng Xihua , Yang Qing , Chen Ting
Published: July 2024

Table S1. Representativeness of Study Participants
Supplementary Table S4 from MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance
Authors: Davis Lorraine N. , Walker Zachary J. , Reiman Lauren T. , Parzych Sarah E. , Stevens Brett M. , Jordan Craig T. , Forsberg Peter A. , Sherbenou Daniel W.
Published: July 2024

Supplemental Table S4. Cases with Significant Downregulation of IRF4 and MYC mRNA upon ex vivo Pom Treatment Between IMiD-naïve and IMiD-refractory Samples
Supplementary Materials S1 from MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance
Authors: Davis Lorraine N. , Walker Zachary J. , Reiman Lauren T. , Parzych Sarah E. , Stevens Brett M. , Jordan Craig T. , Forsberg Peter A. , Sherbenou Daniel W.
Published: July 2024

Supplementary Reagents tables and text
Supplementary Table 5 from Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification
Authors: Lorentzen Georgia M. , Łaniewski Paweł , Cui Haiyan , Mahnert Nichole D. , Mourad Jamal , Borst Matthew P. , Willmott Lyndsay , Chase Dana M. , Roe Denise J. , Herbst-Kralovetz Melissa M.
Published: July 2024

Significance levels of metabolites after adjustment for age and BMI. A linear regression model was used, and p-values were adjusted using Dunnett adjustment.
Supplementary Table S7 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Authors: Son Ji , Zhang Yingao , Lin Heather , Mirallas Oriol , Alvarez Ballesteros Pablo , Nardo Mirella , Clark Natalie , Hillman R. Tyler , Campbell Erick , Holla Vijaykumar , Johnson Amber M. , Biter Amadeo B. , Yuan Ying , Cobb Lauren P. , Gershenson David M. , Jazaeri Amir A. , Lu Karen H. , Soliman Pamela T. , Westin Shannon N. , Euscher Elizabeth D. , Lawson Barrett C. , Yang Richard K. , Meric-Bernstam Funda , Hong David S.
Published: July 2024

Clinical efficacy of KRAS G12C inhibitors in gynecologic cancer patients with KRAS G12C mutation
Supplementary Table S5 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Authors: Son Ji , Zhang Yingao , Lin Heather , Mirallas Oriol , Alvarez Ballesteros Pablo , Nardo Mirella , Clark Natalie , Hillman R. Tyler , Campbell Erick , Holla Vijaykumar , Johnson Amber M. , Biter Amadeo B. , Yuan Ying , Cobb Lauren P. , Gershenson David M. , Jazaeri Amir A. , Lu Karen H. , Soliman Pamela T. , Westin Shannon N. , Euscher Elizabeth D. , Lawson Barrett C. , Yang Richard K. , Meric-Bernstam Funda , Hong David S.
Published: July 2024

Tabulated allelic distribution of gynecologic cancers with RAS mutations
Supplementary Figure 3 from Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification
Authors: Lorentzen Georgia M. , Łaniewski Paweł , Cui Haiyan , Mahnert Nichole D. , Mourad Jamal , Borst Matthew P. , Willmott Lyndsay , Chase Dana M. , Roe Denise J. , Herbst-Kralovetz Melissa M.
Published: July 2024

Receiver operating characteristic (ROC) analysis reveals a multitude of potential biomarkers to detect other EC patients from benign controls. (A) Scatter plot showing the top 15 metabolites with biomarker potential for other EC vs benign controls (AUC>0.8 is considered good and AUC>0.9 is considered excellent). Metabolites are color-coded by superpathway. Uncharacterized metabolites were included in analysis. (B) AUC plots for the top three potential other EC biomarkers showing the AUC values.
Supplementary Figure 2 from Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification
Authors: Lorentzen Georgia M. , Łaniewski Paweł , Cui Haiyan , Mahnert Nichole D. , Mourad Jamal , Borst Matthew P. , Willmott Lyndsay , Chase Dana M. , Roe Denise J. , Herbst-Kralovetz Melissa M.
Published: July 2024

Enrichment analysis reveals pathways altered in endometrila cancer vs benign controls. Enrichment analysis is based on the KEGG pathway database. Bar plots show the top 25 enriched pathways in EC All vs benign controls.
Supplementary Figure S4 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Authors: Son Ji , Zhang Yingao , Lin Heather , Mirallas Oriol , Alvarez Ballesteros Pablo , Nardo Mirella , Clark Natalie , Hillman R. Tyler , Campbell Erick , Holla Vijaykumar , Johnson Amber M. , Biter Amadeo B. , Yuan Ying , Cobb Lauren P. , Gershenson David M. , Jazaeri Amir A. , Lu Karen H. , Soliman Pamela T. , Westin Shannon N. , Euscher Elizabeth D. , Lawson Barrett C. , Yang Richard K. , Meric-Bernstam Funda , Hong David S.
Published: July 2024

Co-mutation analysis of RAS mutations in gynecologic cancers
Supplementary Methods S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
Authors: Chen Yajin , Du Chengyou , Shen Shunli , Zhang Wu , Shan Yunfeng , Lyu Ang , Wu Jianhui , Shang Changzhen , Luo Xuan , Wei Jinxing , Xiao Heng , Qiu Jianguo , Hua Yunpeng , Wang Shutong , Wang Ting , Dai Shengjie , Zhang Shuhao , Xie Bingying , Wu Yinghao , Hao Chunyi
Published: July 2024

Supplementary methods
Supplementary Figure S1 from Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Authors: Son Ji , Zhang Yingao , Lin Heather , Mirallas Oriol , Alvarez Ballesteros Pablo , Nardo Mirella , Clark Natalie , Hillman R. Tyler , Campbell Erick , Holla Vijaykumar , Johnson Amber M. , Biter Amadeo B. , Yuan Ying , Cobb Lauren P. , Gershenson David M. , Jazaeri Amir A. , Lu Karen H. , Soliman Pamela T. , Westin Shannon N. , Euscher Elizabeth D. , Lawson Barrett C. , Yang Richard K. , Meric-Bernstam Funda , Hong David S.
Published: July 2024

Histologic distribution of gynecologic cancers with RAS mutations (n=523)
Supplementary Table S7 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Select adverse events of hypersensitivity/infusion reaction by ADA status (positive, negative) in the RELATIVITY-020 trial
Supplementary Methods S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Authors: Prenen Hans , Deva Sanjeev , Keam Bhumsuk , Lindsay Colin R. , Lugowska Iwona , Yang James C. , Longo Federico , de Miguel Maria , Ponz-Sarvise Mariano , Ahn Myung-Ju , Gumus Mahmut , Champiat Stephane , Italiano Antoine , Salas Sébastien , Perets Ruth , Arslan Cagatay , Cho Byoung C. , Evers Stefan , Boetsch Christophe , Marbach Daniel , Dejardin David , Sleiman Nassim , Ardeshir Caroline , Richard Muriel , Charo Jehad , Kraxner Anton , Keshelava Nino , Teichgräber Volker , Moreno Victor
Published: July 2024

Eligibility criteria and additional study design assessments
Supplementary Table S6 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

(6a) Predicted Relatlimab Exposures at 5th and 95th Percentile of Body Weight Distributions in Patients Receiving 160 mg Q4W and (6b). Predicted Nivolumab Exposures at 5th and 95th Percentile of Body Weight Distributions in Adult 1L MEL Receiving 480 mg Q4W (Relatlimab plus Nivolumab)
Supplementary Table S3 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Parameter Estimates of the Final Relatlimab Population Pharmacokinetic Model
Supplementary Methods S1 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Supplementary Information
Supplementary Figure S8 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Distribution of Model Predicted Relatlimab Exposures (Cavg1 and Cavgss) at 160 mg Q4W by Hepatic Function
Supplementary Figure S6 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Predicted Nivolumab Exposures (Cavg1 and Cavgss) at 480 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adult 1L MEL
Supplementary Figure S5 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Predicted Relatlimab Exposures at 160 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adults
Supplementary Figure S10 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Authors: Zhao Yue , Hu Zheyi , Bathena Sai Praneeth , Keidel Sarah , Miller-Moslin Karen , Statkevich Paul , Bello Akintunde , Roy Amit , Suryawanshi Satyendra
Published: July 2024

Distribution of Predicted Nivolumab Exposures at 480 mg Q4W for Adult ADA+ and ADA- Patients Treated with Relatlimab Plus Nivolumab
Supplementary Data 1 from T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Authors: Verkleij Christie P.M. , O’Neill Chloe A. , Broekmans Marloes E.C. , Frerichs Kristine A. , Bruins Wassilis S.C. , Duetz Carolien , Kruyswijk Sandy , Baglio Serena R. , Skerget Sheri , Montes de Oca Rocio , Zweegman Sonja , Verona Raluca I. , Mutis Tuna , van de Donk Niels W.C.J.
Published: July 2024

Supplemental Tables S1-S3, Figures S1-S15
Supplementary Data 2 from Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Authors: Peressini Melina , Garcia-Campelo Rosario , Massuti Bartomeu , Martí Cristina , Cobo Manuel , Gutiérrez Vanesa , Dómine Manuel , Fuentes José , Majem Margarita , de Castro Javier , Córdoba Juan F. , Diz María P. , Isla Dolores , Esteban Emilio , Carcereny Enric , Vila Laia , Moreno-Vega Alberto , Ros Silverio , Moreno Amaia , García Francisco J. , Huidobro Gerardo , Aguado Carlos , Cebey-López Victor , Valdivia Javier , Palmero Ramón , Lianes Pilar , López-Brea Marta , Vidal Oscar J. , Provencio Mariano , Arriola Edurne , Baena Javier , Herrera Mercedes , Bote Helena , Molero Magdalena , Adradas Vera , Ponce-Aix Santiago , Nuñez-Buiza Angel , Ucero Álvaro , Hernandez Susana , Lopez-Rios Fernando , Conde Esther , Paz-Ares Luis , Zugazagoitia Jon
Published: July 2024

Supplementary File
Supplementary Table S6 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Authors: Bardia Aditya , Sun Sheng , Thimmiah Nayana , Coates James T. , Wu Bogang , Abelman Rachel O. , Spring Laura , Moy Beverly , Ryan Phoebe , Melkonyan Mark N. , Partridge Ann , Juric Dejan , Peppercorn Jeffrey , Parsons Heather , Wander Seth A. , Attaya Victoria , Lormil Brenda , Shellock Maria , Nagayama Aiko , Bossuyt Veerle , Isakoff Steven J. , Tolaney Sara M. , Ellisen Leif W.
Published: July 2024

Table S6: Proportion of patients achieving Objective Response (OR), per RECIST, with SG and Talazoparib combination in the phase 1b clinical trial, stratified by biomarkers
Supplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Authors: Bardia Aditya , Sun Sheng , Thimmiah Nayana , Coates James T. , Wu Bogang , Abelman Rachel O. , Spring Laura , Moy Beverly , Ryan Phoebe , Melkonyan Mark N. , Partridge Ann , Juric Dejan , Peppercorn Jeffrey , Parsons Heather , Wander Seth A. , Attaya Victoria , Lormil Brenda , Shellock Maria , Nagayama Aiko , Bossuyt Veerle , Isakoff Steven J. , Tolaney Sara M. , Ellisen Leif W.
Published: July 2024

Table S5: Treatment Efficacy with SG and Talazoparib combination in the phase 1b clinical trial
Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Authors: Bardia Aditya , Sun Sheng , Thimmiah Nayana , Coates James T. , Wu Bogang , Abelman Rachel O. , Spring Laura , Moy Beverly , Ryan Phoebe , Melkonyan Mark N. , Partridge Ann , Juric Dejan , Peppercorn Jeffrey , Parsons Heather , Wander Seth A. , Attaya Victoria , Lormil Brenda , Shellock Maria , Nagayama Aiko , Bossuyt Veerle , Isakoff Steven J. , Tolaney Sara M. , Ellisen Leif W.
Published: July 2024

Figure S4. Results of phase 1b clinical trial of SG and talazoparib